Summary

The global bioactive dressings market is projected to reach USD 5.8 billion by 2029 from USD 3.5 billion in 2024, at a CAGR of 10.5% during the forecast period. The rising incidence of chronic wounds and the increasing elderly population are the major drivers boosting the demand for bioactive dressings. Technology advancements in wound dressings and increased awareness of the benefits like faster healing and patient comfort, are driving market growth, with further expansion anticipated due to ongoing innovation.
“Bioactive dressings segment accounted for the highest market share in the bioactive dressings market, by product type, during the forecast period.”
Based on product type, the bioactive dressings market is divided into bioactive dressings and skin substitutes. In 2023, the bioactive dressings segment led the market. The growth of this segment is primarily driven by the increasing prevalence of chronic, surgical, and traumatic wounds; a rising number of burn injuries; technological advancements in bioactive dressings; and increased spending on the treatment of chronic and surgical wounds
“Chronic wound segment accounted for the highest market share in the bioactive dressings market, by application, during the forecast period.”
Based on application, the bioactive dressings market is divided into acute wounds and chronic wounds. In 2023, the chronic wounds segment held the largest market share. The majority share of this segment is attributed to the increasing elderly population and the rising incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers, arterial ulcers and venous leg ulcers, among others.
“Home Care Settings accounted for the highest CAGR during the forecast period.”
Based on end user, the bioactive dressings market is segmented into hospitals and clinics, long-term care facilities, home care settings, and other end users. In 2023, hospitals and clinics held the largest market share. However, home care settings are projected to grow at the highest CAGR during the forecast period, mainly due to their cost-efficiency compared to hospitals, as well as the convenience and comfort they offer.
“The North America segment accounted for the highest market share in the bioactive dressings market, by region, during the forecast period.”
Bioactive dressings market is divided into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), the Middle East & Africa (MEA) and GCC Countries. During the forecast period the North America is expected to witness a larger market share. The expansion of the bioactive dressings market in North America is fueled by the high prevalence of chronic wounds, advancements in bioactive dressing technologies, and increased healthcare spending.

Breakdown of supply-side primary interviews by company type, designation, and region:
• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (42%), Asia- Pacific (31%), Europe (20%), Latin America- (4%) and MEA-(2%), and GCC (1%).

Prominent companies include 3M (US), Smith+Nephew (UK), Cardinal Health (US), B. Braun SE (Germany), Mölnlycke Health Care AB (Sweden), Convatec Inc. (UK), Paul Hartmann Ag (Germany), Coloplast Corp (Denmark), Integra LifeSciences Corporation (US), Organogenesis Inc.(US), Essity(Sweden), Covalon Technologies(Canada), Mimedx Group, Inc.(US), Sanara Medtech Inc.(US), Medline Industries, LP.(US), Hollister Incorporated(US), Lohmann & Rauscher (L&R) (Germany), DermaRite Industries, LLC (US), BioTissue (US), LifeNet Health (US), Advancis Medical(UK), Human BioSciences (US), AMERX Health Care (US), Gentell (US) and Axio Biosolutions Pvt Ltd (India).

Research Coverage
This research report categorizes the bioactive dressings market by product type, property type, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the bioactive dressings market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product launches, mergers and acquisitions, and recent developments associated with the bioactive dressings market. Competitive analysis of upcoming startups in the bioactive dressings market ecosystem is covered in this report.





Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall bioactive dressings market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the bioactive dressings market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the bioactive dressings market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the bioactive dressings market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioactive dressings market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like 3M (US), Smith+Nephew (UK), Cardinal Health (US), B. Braun SE (Germany), Mölnlycke Health Care AB (Sweden), Convatec Inc. (UK), Paul Hartmann Ag (Germany), Coloplast Corp (Denmark), Integra LifeSciences Corporation (US), Organogenesis Inc.(US), Covalon Technologies(Canada), and Mimedx Group, Inc.(US) among others in the bioactive dressings market strategies.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS 32
1.3 MARKET SCOPE 33
1.3.1 BIOACTIVE DRESSINGS MARKET SEGMENTATION 33
1.3.2 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 37
2.1.2.1 Primary sources 37
2.1.2.2 Key data from primary sources 38
2.1.2.3 Key industry insights 39
2.1.2.4 Breakdown of primary interviews 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
2.2.1.1 Approach 1: Company revenue estimation approach 41
2.2.1.2 Approach 3: Presentations of companies and primary interviews 41
2.2.1.3 Growth forecast 41
2.2.1.4 CAGR projections 42
2.2.2 TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
2.4 STUDY ASSUMPTIONS 45
2.4.1 GROWTH RATE ASSUMPTIONS 45
2.4.2 LIMITATIONS 45
2.5 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 BIOACTIVE DRESSINGS MARKET OVERVIEW 51
4.2 BIOACTIVE DRESSINGS MARKET SHARE, BY PRODUCT, 2024 VS. 2029 52
4.3 BIOACTIVE DRESSINGS MARKET SHARE, BY TYPE, 2024 VS. 2029 52
4.4 SKIN SUBSTITUTES MARKET SHARE, BY TYPE, 2024 VS. 2029 53
4.5 BIOACTIVE DRESSINGS MARKET SHARE, BY PROPERTY TYPE, 2024 VS. 2029 53
4.6 BIOACTIVE DRESSINGS MARKET SHARE, BY APPLICATION, 2024 VS. 2029 54
4.7 BIOACTIVE DRESSINGS MARKET SHARE FOR CHRONIC WOUNDS,
BY TYPE, 2024 VS. 2029 54
4.8 BIOACTIVE DRESSINGS MARKET SHARE FOR ACUTE WOUNDS, BY TYPE, 2024 VS. 2029 55
4.9 BIOACTIVE DRESSINGS MARKET SHARE, BY END USER, 2024 VS. 2029 55
4.10 BIOACTIVE DRESSINGS MARKET SHARE FOR HOSPITALS & CLINICS,
BY TYPE, 2024 VS. 2029 56
4.11 BIOACTIVE DRESSINGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
5.2.1.1 Rising prevalence of chronic wounds 58
5.2.1.2 Growing geriatric population 58
5.2.1.3 Increasing number of surgical procedures worldwide 59
5.2.1.4 Increasing incidence of burn injuries 60
5.2.1.5 Advancements in bioactive dressing technology 60
5.2.2 RESTRAINTS 61
5.2.2.1 High costs of bioactive dressing products 61
5.2.2.2 Limited reimbursement policies 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Growth potential of emerging countries 62
5.2.3.2 New product development 62
5.2.3.3 Strategic collaboration between market players 63
5.2.4 CHALLENGES 64
5.2.4.1 Difficult regulatory approval process 64
5.2.4.2 Lack of awareness and education 64
5.3 PRICING ANALYSIS 65
5.3.1 AVERAGE SELLING PRICE TREND OF BIOACTIVE DRESSINGS 65
5.3.2 AVERAGE SELLING PRICE OF BIOACTIVE DRESSINGS, BY REGION 66
5.4 PATENT ANALYSIS 67
5.4.1 LIST OF MAJOR PATENTS 68
5.5 VALUE CHAIN ANALYSIS 69
5.6 SUPPLY CHAIN ANALYSIS 70
5.7 ECOSYSTEM ANALYSIS 72
5.7.1 BIOACTIVE DRESSINGS MARKET: ROLE IN ECOSYSTEM 73
5.8 PORTER’S FIVE FORCES ANALYSIS 74
5.8.1 THREAT OF NEW ENTRANTS 75
5.8.2 THREAT OF SUBSTITUTES 75
5.8.3 BARGAINING POWER OF BUYERS 75
5.8.4 BARGAINING POWER OF SUPPLIERS 75
5.8.5 DEGREE OF COMPETITION 75
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 76
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
5.9.2 BUYING CRITERIA 76
5.10 REGULATORY ANALYSIS 77
5.10.1 REGULATORY LANDSCAPE 77
5.10.1.1 North America 77
5.10.1.1.1 US 77
5.10.1.1.2 Canada 77
5.10.1.2 Europe 78
5.10.1.3 Asia Pacific 78
5.10.1.3.1 China 78
5.10.1.3.2 Japan 78
5.10.1.3.3 India 78
5.10.1.4 Latin America 78
5.10.1.4.1 Brazil 79
5.10.1.4.2 Mexico 79
5.10.1.5 Middle East 79
5.10.1.6 Africa 79
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
5.11 TRADE ANALYSIS 81
5.11.1 TRADE ANALYSIS FOR WADDING, GAUZE, AND BANDAGES 81
5.12 TECHNOLOGY ANALYSIS 83
5.12.1 KEY TECHNOLOGIES 83
5.12.1.1 Kollagen technology 83
5.12.2 COMPLEMENTARY TECHNOLOGIES 83
5.12.2.1 Bioactive microfiber gelling technology 83
5.12.3 ADJACENT TECHNOLOGIES 84
5.12.3.1 Kerecis intact fish skin technology 84
5.13 KEY CONFERENCES & EVENTS, 2024–2025 84
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86
5.15 INVESTMENT & FUNDING SCENARIO 87
5.16 IMPACT OF AI ON BIOACTIVE DRESSINGS MARKET 87
6 BIOACTIVE DRESSINGS MARKET, BY PRODUCT 89
6.1 INTRODUCTION 90
6.2 BIOACTIVE DRESSINGS 90
6.2.1 COLLAGEN DRESSINGS 93
6.2.1.1 Unique healing properties and biocompatibility to drive growth 93
 
6.2.2 ALGINATE DRESSINGS 96
6.2.2.1 Excellent absorption capacity to boost demand for alginate dressings 96
6.2.3 CHITOSAN DRESSINGS 99
6.2.3.1 Rising need for effective, natural wound healing options to
support market growth 99
6.2.4 HONEY DRESSINGS 101
6.2.4.1 Effective and natural wound care management to fuel growth 101
6.2.5 OTHER BIOACTIVE DRESSINGS 104
6.3 SKIN SUBSTITUTES 107
6.3.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS 110
6.3.1.1 High efficacy of human donor tissue-derived products to support market demand 110
6.3.2 ACELLULAR ANIMAL-DERIVED PRODUCTS 113
6.3.2.1 Recognition of importance of ECM in wound treatment to boost development of acellular wound care biologics 113
6.3.3 BIOSYNTHETIC PRODUCTS 116
6.3.3.1 Increased bioburden of infected wounds to stimulate market growth 116
7 BIOACTIVE DRESSINGS MARKET, BY PROPERTY TYPE 119
7.1 INTRODUCTION 120
7.2 NON-ANTIMICROBIAL DRESSINGS 120
7.2.1 COST-EFFECTIVENESS COMPARED TO ANTIMICROBIAL DRESSINGS TO BOOST MARKET 120
7.3 ANTIMICROBIAL DRESSINGS 123
7.3.1 EFFECTIVENESS IN PREVENTING AND MANAGING INFECTIONS TO
DRIVE GROWTH 123
8 BIOACTIVE DRESSINGS MARKET, BY APPLICATION 127
8.1 INTRODUCTION 128
8.2 CHRONIC WOUNDS 128
8.2.1 DIABETIC FOOT ULCERS 131
8.2.1.1 Increasing prevalence of diabetes to drive growth 131
8.2.2 PRESSURE ULCERS 135
8.2.2.1 Growing geriatric population to drive demand for bioactive dressings 135
8.2.3 VENOUS LEG ULCERS 138
8.2.3.1 Rising prevalence of obesity to boost adoption 138
8.2.4 OTHER CHRONIC WOUNDS 141
8.3 ACUTE WOUNDS 143
8.3.1 SURGICAL WOUNDS 146
8.3.1.1 Rising volume of surgical procedures to support market growth 146
8.3.2 TRAUMATIC WOUNDS 149
8.3.2.1 Increasing number of road accidents to drive growth 149
8.3.3 BURNS 152
8.3.3.1 High incidence of burn injuries to propel market growth 152
9 BIOACTIVE DRESSINGS MARKET, BY END USER 156
9.1 INTRODUCTION 157
9.2 HOSPITALS & CLINICS 157
9.2.1 INPATIENT SETTINGS 161
9.2.1.1 Increasing hospital admissions due to HAIs to drive growth 161
9.2.2 OUTPATIENT SETTINGS 164
9.2.2.1 Rising costs of inpatient facilities to drive demand for
outpatient care settings 164
9.3 HOME CARE SETTINGS 167
9.3.1 LOW COSTS AND CONVENIENCE TO DRIVE GROWTH 167
9.4 LONG-TERM CARE FACILITIES 170
9.4.1 GROWTH IN GERIATRIC & VULNERABLE POPULATIONS TO BOOST DEMAND FOR BETTER LONG-TERM CARE 170
9.5 OTHER END USERS 173
10 BIOACTIVE DRESSINGS MARKET, BY REGION 177
10.1 INTRODUCTIONS 178
10.2 NORTH AMERICA 178
10.2.1 US 184
10.2.1.1 Rising prevalence of chronic diseases to drive market 184
10.2.2 CANADA 187
10.2.2.1 Growing awareness about diabetes and its associated complications to fuel market 187
10.3 EUROPE 192
10.3.1 GERMANY 196
10.3.1.1 Rising focus on medical technology clusters to boost market 196
10.3.2 UK 200
10.3.2.1 Increasing prevalence of surgeries to aid growth 200
10.3.3 FRANCE 204
10.3.3.1 Surge in elderly population to propel market 204
10.3.4 ITALY 208
10.3.4.1 Improved life expectancy to support growth 208
10.3.5 SPAIN 211
10.3.5.1 Increasing median age to augment growth 211
10.3.6 REST OF EUROPE 215
10.4 ASIA PACIFIC 218
10.4.1 CHINA 223
10.4.1.1 Growing incidence of diabetic foot ulceration to drive market 223
10.4.2 JAPAN 227
10.4.2.1 Expanding hospital infrastructure to fuel market 227
10.4.3 INDIA 230
10.4.3.1 Booming medical tourism in India to boost market 230
10.4.4 REST OF ASIA PACIFIC 234
10.5 LATIN AMERICA 238
10.5.1 BRAZIL 242
10.5.1.1 Presence of large patient population to stimulate growth 242
10.5.2 MEXICO 245
10.5.2.1 Growing awareness about effective wound care approaches to support growth 245
10.5.3 REST OF LATIN AMERICA 249
10.6 MIDDLE EAST & AFRICA 252
10.6.1 GROWING DEMAND FOR HEALTHCARE FACILITIES TO AID MARKET GROWTH 252
10.7 GCC COUNTRIES 256
10.7.1 FAVORABLE HEALTHCARE INFRASTRUCTURE AND INITIATIVES
TO BOOST MARKET 256
11 COMPETITIVE LANDSCAPE 260
11.1 OVERVIEW 260
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 260
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOACTIVE DRESSINGS MARKET 261
11.3 REVENUE ANALYSIS 263
11.4 MARKET SHARE ANALYSIS 264
11.4.1 RANKING OF KEY MARKET PLAYERS 265
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 266
11.5.1 STARS 266
11.5.2 EMERGING LEADERS 266
11.5.3 PERVASIVE PLAYERS 266
11.5.4 PARTICIPANTS 266
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 268
11.5.5.1 Company footprint 268
11.5.5.2 Product footprint 268
11.5.5.3 Property footprint 268
11.5.5.4 Application footprint 269
11.5.5.5 Region footprint 269
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 269
11.6.1 PROGRESSIVE COMPANIES 269
11.6.2 RESPONSIVE COMPANIES 270
11.6.3 DYNAMIC COMPANIES 270
11.6.4 STARTING BLOCKS 270
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 272
11.7 COMPANY VALUATION & FINANCIAL METRICS 273
11.7.1 FINANCIAL METRICS 273
11.7.2 COMPANY VALUATION 273
11.8 BRAND/PRODUCT COMPARISON 274
 
11.9 COMPETITIVE SCENARIO 274
11.9.1 PRODUCT LAUNCHES AND APPROVALS 274
11.9.2 DEALS 275
11.9.3 EXPANSIONS 276
11.9.4 OTHER DEVELOPMENTS 276
12 COMPANY PROFILES 277
12.1 KEY PLAYERS 277
12.1.1 SMITH+NEPHEW 277
12.1.1.1 Business overview 277
12.1.1.2 Products offered 278
12.1.1.3 Recent developments 279
12.1.1.3.1 Expansions 279
12.1.1.3.2 Other developments 280
12.1.1.4 MnM view 280
12.1.1.4.1 Key strengths 280
12.1.1.4.2 Strategic choices 280
12.1.1.4.3 Weaknesses and competitive threats 280
12.1.2 ORGANOGENESIS INC. 281
12.1.2.1 Business overview 281
12.1.2.2 Products offered 282
12.1.2.3 Recent developments 283
12.1.2.3.1 Product approvals 283
12.1.2.3.2 Other developments 284
12.1.2.4 MnM view 284
12.1.2.4.1 Key strengths 284
12.1.2.4.2 Strategic choices 284
12.1.2.4.3 Weaknesses and competitive threats 284
12.1.3 MIMEDX GROUP, INC. 285
12.1.3.1 Business overview 285
12.1.3.2 Products offered 286
12.1.3.3 Recent developments 287
12.1.3.3.1 Product launches and approvals 287
12.1.3.3.2 Deals 287
12.1.3.4 MnM view 288
12.1.3.4.1 Key strengths 288
12.1.3.4.2 Strategic choices 288
12.1.3.4.3 Weaknesses and competitive threats 288
12.1.4 3M 289
12.1.4.1 Business overview 289
12.1.4.2 Products offered 290
12.1.4.3 Recent developments 292
12.1.4.3.1 Other developments 292
12.1.4.4 MnM view 292
12.1.4.4.1 Key strengths 292
12.1.4.4.2 Strategic choices 292
12.1.4.4.3 Weaknesses and competitive threats 292
12.1.5 CARDINAL HEALTH 293
12.1.5.1 Business overview 293
12.1.5.2 Products offered 294
12.1.5.3 MnM view 295
12.1.5.3.1 Key strengths 295
12.1.5.3.2 Strategic choices 295
12.1.5.3.3 Weaknesses and competitive threats 296
12.1.6 B. BRAUN SE 297
12.1.6.1 Business overview 297
12.1.6.2 Products offered 299
12.1.7 MÖLNLYCKE AB 300
12.1.7.1 Business overview 300
12.1.7.2 Products offered 301
12.1.8 CONVATEC INC. 302
12.1.8.1 Business overview 302
12.1.8.2 Products offered 303
12.1.8.3 Recent developments 305
12.1.8.3.1 Product approvals 305
12.1.8.3.2 Deals 305
12.1.9 PAUL HARTMANN AG 306
12.1.9.1 Business overview 306
12.1.9.2 Products offered 307
12.1.10 COLOPLAST CORP. 309
12.1.10.1 Business overview 309
12.1.10.2 Products offered 310
12.1.10.3 Recent developments 311
12.1.10.3.1 Deals 311
12.1.11 INTEGRA LIFESCIENCES CORPORATION 312
12.1.11.1 Business overview 312
12.1.11.2 Products offered 313
12.1.11.3 Recent developments 316
12.1.11.3.1 Deals 316
12.1.12 ESSITY AKTIEBOLAG 317
12.1.12.1 Business overview 317
12.1.12.2 Products offered 318
12.1.12.3 Recent developments 319
12.1.12.3.1 Product launches 319
12.1.12.3.2 Deals 319
12.1.13 COVALON TECHNOLOGIES LTD. 320
12.1.13.1 Business overview 320
12.1.13.2 Products offered 321
12.1.13.3 Recent developments 321
12.1.13.3.1 Other developments 321
12.1.14 SANARA MEDTECH 322
12.1.14.1 Business overview 322
12.1.14.2 Products offered 323
12.1.14.3 Recent developments 324
12.1.14.3.1 Product launches 324
12.1.14.3.2 Deals 324
12.2 OTHER PLAYERS 325
12.2.1 MEDLINE INDUSTRIES, INC. 325
12.2.2 HOLLISTER INCORPORATED 326
12.2.3 L&R GROUP 327
12.2.4 DERMARITE INDUSTRIES, LLC 328
12.2.5 BIOTISSUE 329
12.2.6 LIFENET HEALTH 330
12.2.7 ADVANCIS MEDICAL 331
12.2.8 HUMAN BIOSCIENCES 332
12.2.9 AMERX HEALTH CARE 333
12.2.10 GENTELL 334
12.2.11 AXIO BIOSOLUTIONS PVT. LTD. 335
13 APPENDIX 336
13.1 DISCUSSION GUIDE 336
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 340
13.3 CUSTOMIZATION OPTIONS 342
13.4 RELATED REPORTS 342
13.5 AUTHOR DETAILS 343